Treatment Recommendation for Hepatitis C Genotype 1, F1-F2 Fibrosis
For this treatment-naïve patient with chronic hepatitis C genotype 1, F1-F2 fibrosis (no cirrhosis), and viral load of 400,000 IU/mL, initiate sofosbuvir/ledipasvir (400mg/90mg) as a single fixed-dose tablet once daily for 12 weeks without ribavirin. 1
Rationale and Treatment Algorithm
This recommendation is based on the EASL 2016 guidelines which provide the most comprehensive framework for HCV treatment decisions 1. Your patient falls into a straightforward category that allows for simplified treatment:
Key Decision Points:
Treatment Status: Treatment-naïve (no prior HCV therapy)
Fibrosis Stage: F1-F2 (no cirrhosis) - This is critical because it allows for standard 12-week duration without ribavirin
Viral Load: 400,000 IU/mL - This is below the 6 million IU/mL threshold, which means even shorter 8-week treatment could be considered, though 12 weeks remains the standard recommendation 1
Genotype: The patient needs genotype 1 subtyping (1a vs 1b) to be confirmed, but sofosbuvir/ledipasvir works equally well for both subtypes in treatment-naïve patients without cirrhosis
Alternative Equivalent Options
The EASL guidelines explicitly state these regimens are considered equivalent for genotype 1 1:
- Sofosbuvir/velpatasvir (400mg/100mg) once daily for 12 weeks without ribavirin 1
- Grazoprevir/elbasvir for 12 weeks without ribavirin (if genotype 1b or genotype 1a without baseline resistance-associated substitutions)
- Ombitasvir/paritaprevir/ritonavir plus dasabuvir - though this requires genotype 1 subtyping and has more complex dosing 1
Why Not Ribavirin?
Ribavirin is not needed in your patient because 1:
- Treatment-naïve status
- No cirrhosis (F1-F2 fibrosis only)
- Standard 12-week duration is sufficient
Ribavirin would only be added if the patient were treatment-experienced with genotype 1a or had specific resistance-associated substitutions detected on testing 1.
Expected Outcomes
With sofosbuvir/ledipasvir for 12 weeks, expect sustained virological response (SVR12) rates of 97-99% based on the ION clinical trial data 1. This essentially represents cure of hepatitis C infection, which will:
- Halt fibrosis progression
- Reduce risk of hepatocellular carcinoma
- Improve long-term morbidity and mortality
Important Caveats
Drug Interactions: Check for interactions with any concomitant medications, particularly antiretrovirals if HIV coinfection exists, though none is mentioned in this case 2
Monitoring: The patient should have HCV RNA checked at week 12 (end of treatment) and again 12 weeks post-treatment to confirm SVR12
Fibrosis Surveillance: Even after achieving SVR, patients with F2 fibrosis should continue periodic monitoring for fibrosis progression, though the risk is substantially reduced after viral eradication 3
Genotype Confirmation: While treatment can proceed, confirm the exact genotype (1a vs 1b) as this may influence alternative regimen selection if sofosbuvir/ledipasvir is unavailable
The elevated alpha-2-macroglobulin (302 mg/dL, reference 110-276) noted in the FibroSure panel is consistent with the inflammatory activity but does not change the treatment approach.